Evidence map›Paper›PMID 27051417›Full record

ReviewGastroenterology research and practice2016

Thermal Ablative Therapies and Immune Checkpoint Modulation: Can Locoregional Approaches Effect a Systemic Response?

Amol Mehta, Rahmi Oklu, Rahul A Sheth

Registry-linked trialAbstract readReview
In one paragraph

Review in Gastroenterology research and practice, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04429321 (UPCC06820 Phase 1 Trial of Nivolumab + Ipilimumab With Immunostimulatory Embolization for Stage 4 Renal Cell Carcinoma With Unresected Primary), which is not on this map. Cited by 65 papers.

0numbers the graph read from it
0cells of the map it votes in
65citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04429321 phase1terminatednot on this mapstarted 2020, after this paper: background citation

UPCC06820 Phase 1 Trial of Nivolumab + Ipilimumab With Immunostimulatory Embolization for Stage 4 Renal Cell Carcinoma With Unresected Primary

TypeinterventionalSponsorAbramson Cancer Center at Penn MedicineRan2020 to 2024Enrolled1ConditionsRenal Cell Carcinoma, Renal Cell Carcinoma Stage IVArmsNivolumab, Ipilimumab, bland embolization
3 · Its place in the literature

Who cites it

65 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Safety and efficacy of co-ablationJournal of thoracic disease · 2025
    Article
  15. Imaging in Interventional Radiology: Breast Cryoablation.Seminars in interventional radiology · 2025
    Review
  16. Review
  17. Article
  18. Tissue Ablation: Applications and Perspectives.Advanced materials (Deerfield Beach, Fla.) · 2024
    Review
  19. Article
  20. Review

5 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Amol MehtaUniversity of Pittsburgh, Pittsburgh, PA 15213, USA.
Rahmi OkluMayo Clinic, Scottsdale, AZ 85259, USA.
Rahul A ShethMD Anderson Cancer Center, Houston, TX 77030, USA.ORCID 0000-0001-9615-8985

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Percutaneous image-guided ablation is an increasingly common treatment for a multitude of solid organ malignancies. While historically these techniques have been restricted to the management of small, unresectable tumors, there is an expanding appreciation for the systemic effects these locoregional interventions can cause. In this review, we summarize the mechanisms of action for the most common thermal ablation modalities and highlight the key advances in knowledge regarding the interactions between thermal ablation and the immune system.

Identifiers

PMID27051417
PMCPMC4802022

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.